Sale

Oral Antibiotics Market

Global Oral Antibiotics Market Size, Share, Value, Report: By Penicillin’s, Cephalosporins, Macrolides, Fluoroquinolones, Tetracyclines, Sulfonamides and Trimethoprim, Others; By Spectrum of Antibiotics: Broad Spectrum Antibiotics, Others; By Applications; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Oral Antibiotics Market Outlook

The global oral antibiotics market size was valued at USD 18.5 billion in 2023, driven by the rising incidence of infectious diseases across the globe. The market is expected to grow at a CAGR of 2.5% during the forecast period of 2024-2032, with the values likely to rise from USD 18.96 billion in 2024 to USD 23.1 billion by 2032.

 

Oral Antibiotics: Introduction

Oral antibiotics refer to medical drugs such as tablets and capsules that are administered orally and are used to treat mild to moderate infections in the body. They eliminate the risk of canula-related infections to enhance the cost-effectiveness while effectively treating infectious diseases. Moreover, oral antibiotics are typically used to kill microbes in the body.

 

Global Oral Antibiotics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Oral Antibiotics Market Analysis

With the rising incidence of chronic diseases like influenza and tuberculosis, the oral antibiotics market demand has grown in the historical period. The growing prevalence of urinary tract infections (UTIs), especially in women, has significantly boosted the demand for oral antibiotics such as Fosfomycin and ceftriaxone, among others.

 

With the sudden COVID-19 outbreak, the approvals for oral antibiotics by government bodies have seen an upswing. This can be attributed to enhance the treatment options for infectious diseases. In September 2023, the FDA granted its approval for Canada based Appili Therapeutics' liquid form of antibiotic drug called metronidazole. This liquid oral form is an effective alternative for those who are unable to administer antibiotics through injections or pills.

 

The oral antibiotics market growth is further driven by a profound emphasis on battling antibiotic resistance. A global non-profit organization CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has awarded the researchers from the University of Melbourne with a whopping USD 1.75 million to develop an oral therapeutic that can restore the activity of antibiotics used to treat pneumonia. Such investments are expected to foster innovation and bring effective treatment alternatives for patients across the globe.

 

Global Oral Antibiotics Market Segmentation

 

Global Oral Antibiotics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Class

  • Penicillin’s
  • Cephalosporins
  • Macrolides
  • Fluoroquinolones
  • Tetracyclines
  • Sulfonamides and Trimethoprim
  • Others

 

Market Breakup by Spectrum of Antibiotics

  • Broad Spectrum Antibiotics
  • Mid and Narrow Spectrum Antibiotics

 

Market Breakup by Applications

  • Respiratory Infections
  • Urinary Tract Infections (UTIs)
  • Skin Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Infections (STIs)
  • Others

 

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Oral Antibiotics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Oral Antibiotics Market Overview

The North America, particularly the United States, has dominated the oral antibiotics market share in the historical period. The market share can be accredited to the increasing number of drug approvals by the government bodies like the FDA. Furthermore, the region is experiencing several mergers and acquisitions wherein the healthcare giants are acquiring smaller companies to foster innovation and growth.

 

The Asia Pacific region is anticipated to experience a surge in the oral therapeutics market value, aided by improving research and healthcare infrastructure. In addition, the rising privatization in countries like India is driving the market forward with rapid adoption of latest technologies. There is immense focus on combating antibiotic resistance, with new seminars being arranged to educate the scientific community.

 

Europe, with a robust research infrastructure, is another centre of innovation for the oral antibiotics market. It is a huge market for oral antibiotic consumption, with a substantial amount of geriatric population, that is more prone to chronic diseases. The presence of several academic institutions and prominent pharmaceutical companies plays a major role in contributing to the significant market size.

 

Global Oral Antibiotics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • AstraZeneca plc.
  • Roche Holding AG
  • Bayer AG
  • Johnson & Johnson
  • Sanofi
  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • Abbott Laboratories
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Class
  • Spectrum of Antibiotics
  • Applications
  • Distribution Channel
  • Region
Breakup by Class
  • Penicillin’s
  • Cephalosporins
  • Macrolides
  • Fluoroquinolones
  • Tetracyclines
  • Sulfonamides and Trimethoprim
  • Others
Breakup by Spectrum of Antibiotics
  • Broad Spectrum Antibiotics
  • Mid and Narrow Spectrum Antibiotics
Breakup by Applications
  • Respiratory Infections
  • Urinary Tract Infections (UTIs)
  • Skin Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Infections (STIs)
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • AstraZeneca plc.
  • Roche Holding AG
  • Bayer AG
  • Johnson & Johnson
  • Sanofi
  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • Abbott Laboratories
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Oral Antibiotics Market Overview 

    3.1    Global Oral Antibiotics Market Historical Value (2017-2023) 
    3.2    Global Oral Antibiotics Market Forecast Value (2024-2032)
4    Global Oral Antibiotics Market Landscape
    4.1    Global Oral Antibiotics Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Oral Antibiotics Product Landscape
        4.2.1    Analysis by Class
        4.2.2    Analysis by Applications
5    Global Oral Antibiotics Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Oral Antibiotics Market Segmentation 
    6.1    Global Oral Antibiotics Market by Class
        6.1.1    Market Overview
        6.1.2    Penicillin’s
        6.1.3    Cephalosporins
        6.1.4    Macrolides
        6.1.5    Fluoroquinolones
        6.1.6    Tetracyclines
        6.1.7    Sulfonamides and Trimethoprim
        6.1.8    Others
    6.2    Global Oral Antibiotics Market by Spectrum of Antibiotics
        6.2.1    Market Overview
        6.2.2    Broad Spectrum Antibiotics
        6.2.3    Mid and Narrow Spectrum Antibiotics
    6.3    Global Oral Antibiotics Market by Applications
        6.3.1    Market Overview
        6.3.2    Respiratory Infections
        6.3.3    Urinary Tract Infections (UTIs)
        6.3.4    Skin Infections
        6.3.5    Gastrointestinal Infections
        6.3.6    Sexually Transmitted Infections (STIs)
        6.3.7    Others
    6.4    Global Oral Antibiotics Market by Distribution Channel
        6.4.1    Market Overview
        6.4.2    Hospital Pharmacies
        6.4.3    Retail Pharmacies and Drug Stores
        6.4.4    Online Pharmacies
        6.4.5    Others
    6.5    Global Oral Antibiotics Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Oral Antibiotics Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Oral Antibiotics Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Oral Antibiotics Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Oral Antibiotics Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Oral Antibiotics Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis
    14.1     Analysis by Trial Registration Year
    14.2    Analysis by Trial Status
    14.3    Analysis by Trial Phase
    14.4    Analysis by Therapeutic Area
    14.5    Analysis by Geography
15    Funding and Investment Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    Pfizer Inc.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Novartis AG
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    GlaxoSmithKline plc (GSK)
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Merck & Co., Inc.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    AstraZeneca plc.
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Roche Holding AG
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Bayer AG
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Johnson & Johnson
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Sanofi
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Alkem Laboratories Ltd.
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Cipla Ltd.
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Abbott Laboratories
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Lupin
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Sun Pharmaceutical Industries Ltd.
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    Teva Pharmaceutical Industries Ltd.
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
19    Global Oral Antibiotics Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 18.5 billion in 2023, driven by the rising prevalence of infectious diseases across the globe.

The market is anticipated to grow at a CAGR of 2.5% during the forecast period of 2024-2032, likely to reach a market value of USD 23.1 billion by 2032.

The market demand is fuelled by the growing focus on global health threats like COVID-19, the rising attempts to develop new antibiotics, and the increasing investment in research and development (R&D) activities of oral antibiotics.

The increased approvals for the application of new oral antibiotics is among the recent market trends. In September 2023, Canada based Appili Therapeutics' liquid form of antibiotic drug called metronidazole gained the FDA approval.

Penicillin’s, cephalosporins, macrolides, fluoroquinolones, tetracyclines, sulfonamides and trimethoprim, among others are the common drug classes.

It includes broad spectrum antibiotics as well as mid and narrow spectrum antibiotics.

Common application areas include respiratory infections, urinary tract infections (UTIs), skin infections, gastrointestinal infections, and sexually transmitted infections (STIs), among others.

Major distribution channels include hospital pharmacies, retail pharmacies and drug stores, and online pharmacies, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.

Key players involved in the market are Pfizer Inc., Novartis AG, GlaxoSmithKline plc (GSK), Merck & Co., Inc., AstraZeneca plc., Roche Holding AG, Bayer AG, Johnson & Johnson, Sanofi, Alkem Laboratories Ltd., Cipla Ltd., Lupin, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER